First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Drug | Drug Name | Drug Description |
---|
Drug | Drug Name | Target | Type |
---|
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB18411 | Anbenitamab | 3 | Not Yet Recruiting | 1 |
DB01248 | Docetaxel | 3 | Not Yet Recruiting | 1 |
DB06366 | Pertuzumab | 3 | Not Yet Recruiting | 1 |
DB00072 | Trastuzumab | 3 | Not Yet Recruiting | 1 |